Literature DB >> 3263690

Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

V Jarlier1, M H Nicolas, G Fournier, A Philippon.   

Abstract

Before 1985 at the Pitié-Salpêtrière Hospital in Paris (2,400 beds), resistance to cefotaxime in clinical isolates of Enterobacteriaceae involved only species producing inducible class 1 beta-lactamase. Between November 1985 and April 1987, however, 62 isolates (57 of Klebsiella pneumoniae and five of Escherichia coli) showed decreased susceptibility to cefotaxime (mean MIC, 8-16 micrograms/mL). The transferability of cefotaxime resistance in E. coli K12 was demonstrated for 15 of 16 selected isolates. By isoelectric focusing using iodometric detection with 20 mg of ceftriaxone/100 mL and determination of substrate and inhibition profiles, three beta-lactamases mediating cefotaxime resistance were identified as SHV-2 (isoelectric point [pI] 7.6), CTX-1 (pI 6.3), and "SHV-2-type" or SHV-3 (pI 6.98). The three beta-lactamases hydrolyzed penicillins and cephalosporins (including cefotaxime and ceftriaxone) and were therefore designated "extended broad-spectrum beta-lactamases" (EBS-Bla). The enzymes conferred to derivatives a high level of resistance to amoxicillin, ticarcillin, piperacillin, and cephalothin and a decreased degree of susceptibility (i.e., MICs increased by 10- to 800-fold) to cefotaxime, ceftriaxone, ceftazidime, and aztreonam. These beta-lactamases did not affect the activity of cephamycins (cefoxitin, cefotetan, moxalactam) or imipenem. Synergy between clavulanate or sulbactam (2 micrograms/mL) and amoxicillin was greater against derivatives producing EBS-Bla than against those producing TEM-1, TEM-2, or SHV-1; this synergy was greater with clavulanate than with sulbactam against derivatives producing SHV-2 and the SHV-2-type enzyme but was similar with clavulanate and sulbactam against those producing CTX-1. A double-disk synergy test performed with cefotaxime and Augmentin disks (placed 30 mm apart, center to center) seemed a useful and specific test for the detection of strains producing EBS-Bla.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263690     DOI: 10.1093/clinids/10.4.867

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  444 in total

1.  Evidence of in vivo transfer of a plasmid encoding the extended-spectrum beta-lactamase TEM-24 and other resistance factors among different members of the family Enterobacteriaceae.

Authors:  C Neuwirth; E Siebor; A Pechinot; J M Duez; M Pruneaux; F Garel; A Kazmierczak; R Labia
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Characterization of TEM-56, a novel beta-lactamase produced by a Klebsiella pneumoniae clinical isolate.

Authors:  C Neuwirth; R Labia; E Siebor; A Pechinot; S Madec; E B Chaibi; A Kazmierczak
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  What's New in beta-lactamases?

Authors:  Patricia A. Bradford
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  Isolation of an SHV-12 beta-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections.

Authors:  T Teshager; L Domínguez; M A Moreno; Y Saénz; C Torres; S Cardeñosa
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

6.  TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.

Authors:  C Neuwirth; S Madec; E Siebor; A Pechinot; J M Duez; M Pruneaux; M Fouchereau-Peron; A Kazmierczak; R Labia
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland.

Authors:  Anna Baraniak; Janusz Fiett; Agnieszka Sulikowska; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

9.  Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit in the high-prevalence area of Athens, Greece.

Authors:  E Lebessi; H Dellagrammaticas; P T Tassios; L S Tzouvelekis; S Ioannidou; M Foustoukou; N J Legakis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

10.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.